Welcome to our dedicated page for Protagenic Therapeutics news (Ticker: PTIX), a resource for investors and traders seeking the latest updates and insights on Protagenic Therapeutics stock.
Protagenic Therapeutics Inc (PTIX) is a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics targeting stress-related neuropsychiatric and mood disorders. This page serves as the definitive source for official company updates, providing investors and researchers with timely access to validated information about PTIX's scientific advancements and operational developments.
Visitors will find curated press releases covering clinical trial progress, regulatory milestones, research publications, and strategic partnerships. Key focus areas include updates on lead candidate PT00114 – a synthetic TCAP analog designed to modulate stress response systems – along with pipeline developments in anxiety, depression, and PTSD therapeutics.
The resource prioritizes factual reporting on preclinical studies, IND submissions, trial phase transitions, and peer-reviewed data disclosures. Content is organized to highlight material events while maintaining compliance with financial disclosure standards. Regular updates ensure stakeholders can track the company's progress in advancing peptide-based CNS therapies through clinical validation stages.
Bookmark this page for direct access to Protagenic Therapeutics' latest announcements, or subscribe to receive email alerts when new developments occur in this innovative neurotherapeutic research space.
Protagenic Therapeutics (Nasdaq:PTIX) has announced a private placement offering to raise $1.275 million in gross proceeds. The company will issue 1,948,295 shares of common stock at $0.64 per share ($0.89 for insiders), along with series A and B warrants. The series A warrants have an 18-month term while series B warrants extend for 5 years, both with an exercise price of $0.64 per share. Brookline Capital Markets is serving as the sole placement agent. The offering is expected to close by November 4, 2024, with proceeds intended for working capital purposes.
Protagenic Therapeutics (NASDAQ: PTIX) announced promising safety results from the single dose portion of its Phase 1 trial for PT00114, a stress-regulating peptide. The trial involved 30 subjects across five cohorts who received doses up to 1,000 micrograms. No clinically-relevant adverse events were reported. PT00114 aims to address stress, a key factor in psychiatric disorders such as PTSD, depression, anxiety, addiction, and potentially obesity. The multiple dose portion of the trial will commence later this year. An investor call is scheduled for May 22, 2024, at 10:00 am ET to discuss these findings.
Protagenic Therapeutics, Inc. completes enrollment in the single dose portion of Phase 1 trial for PT00114, a synthetic stress-regulating peptide, showing outstanding tolerability. The trial aims to revolutionize treatment for neuropsychiatric disorders like anxiety, depression, PTSD, and addiction. Data from the safety trial phase are expected in May.
FAQ
What is the current stock price of Protagenic Therapeutics (PTIX)?
What is the market cap of Protagenic Therapeutics (PTIX)?
